why it is moving

Abbott Laboratories (NYSE:ABT) posted higher sales of $10.24 billion in the fourth quarter, despite continued soft demand for the company’s Covid-19 testing equipment, beating the consensus of $10.18 billion. Fourth-quarter sales increased 1.5% on a reported basis, 2.1% on an...

Kura Oncology Inc (NASDAQ:KURA) shares are trading higher after the announced $150 million private placement. The stock hit its 52-week high (range of $7.41-$15.96), with a session volume of 958.893K compared to the average volume (100 day) of 1.009 million, according to data from ...

Elevance Health Inc (NYSE:ELV) posted fourth-quarter 2023 revenues of $42.45 billion, up nearly 7% Y/Y, beating the consensus of $42.09 billion.  The increase was driven by higher premium revenue in the Health Benefits segment and growth in pharmacy product revenue in CarelonRx....

Shares of Advances Micro Devices, Inc. (NASDAQ:AMD) rallied strongly in premarket trading on Wednesday as they fell off the all-time closing high of $174.23 reached on Friday. The premarket strength is apparently in reaction a positive analyst action. Late Tuesday, New Street Research analyst...

Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer than 300 drugs. It is designed to expedite the development and reviewing of drugs intended to treat a serious condition...

Sagimet Biosciences Inc (NASDAQ:SGMT) announced topline results from its FASCINATE-2 Phase 2b trial of denifanstat versus placebo in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients with stage 2 or stage 3 fibrosis (F2/F3) at week 52.  Denifanstat showed statistically...

Coherus BioSciences Inc (NASDAQ:CHRS) shares are trading higher after the company agreed to divest its Cimerli ophthalmology franchise to Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) for $170 million plus an additional amount for inventory. This divestiture aligns with Coherus...

Gilead Sciences Inc (NASDAQ:GILD) said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).  EVOKE-01 is evaluating Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel in...

B. Riley Financial Inc (NASDAQ:RILY) is reportedly facing a probe by U.S. authorities over its dealings with Brian Kahn, a key client linked to securities fraud, and the utilization of his assets to secure a loan from Nomura Holdings Inc (NYSE:NMR).  The U.S. Securities...

Stifel upgraded Silk Road Medical Inc (NASDAQ:SILK), noting the newly appointed CEO Chas McKhann’s first public speech at a major competitor healthcare conference, directly addressing/answering most of the concerns/uncertainties leading to Stifel’s downgrade in...

Friday, The Travelers Companies (NYSE:TRV) reported record fourth-quarter earnings surpassing the analysts’ expectations, sending its shares more than 6% higher in the trading session. The New York-based company offers property casualty insurance for auto, home and...

Spirit Airlines Inc (NYSE:SAVE) is reportedly encouraging JetBlue Airways Corporation (NASDAQ:JBLU) to appeal a recent federal judge’s decision blocking their planned $3.8 billion merger. This move comes after U.S. District Judge William Young sided with antitrust...

Novocure Ltd (NASDAQ:NVCR) announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy...

Healthcare insurance firm Humana Inc (NYSE:HUM) cut its fiscal 2023 earnings outlook as the costs of members’ care exceeded its expectations. The company expects 2023 adjusted earnings to be $26.09 a share, per an SEC filing Thursday. Humana had earlier forecast at least $...

Tuesday, Evolus Inc (NASDAQ:EOLS) released preliminary fourth quarter 2023 revenue of approximately $61 million, up 40% Y/Y -and a 22% increase sequentially versus the consensus of $56.97 million, driven primarily by higher volumes from market share gains. Total net revenues for full...